TP53 and acute myeloid leukemia: TP53 mutations within the DNA-binding domain have been associated with poor treatment response and shorter survival in solid tumors.3 Regarding the prognostic relevance of TP53 mutations in AML-CK, Rucker et al.9 showed that TP53 mutation was the most important prognostic factor, outweighing all other variables, but another study demonstrated that there was no significant difference in CR and OS between TP53-mutant and TP53 wild-type patients in this group.10 In this study, we distinctly identified that patients with TP53 mutations had poor prognosis in both total cohort and AML-CK.